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ABSTRACT
....................................................................................................................................................

RESEARCH AND APPLICATIONS

Background As adoption of electronic health records continues to increase, there is an opportunity to incorporate clinical documentation as well as laboratory values and demographics into risk prediction modeling.
Objective The authors develop a risk prediction model for chronic kidney disease (CKD) progression from stage III to stage IV that includes longitudinal data and features drawn from clinical documentation.
Methods The study cohort consisted of 2908 primary-care clinic patients who had at least three visits prior to January 1, 2013 and
developed CKD stage III during their documented history. Development and validation cohorts were randomly selected from this cohort and the study datasets included longitudinal inpatient and outpatient data from these populations. Time series analysis
(Kalman filter) and survival analysis (Cox proportional hazards) were combined to produce a range of risk models. These models
were evaluated using concordance, a discriminatory statistic.
Results A risk model incorporating longitudinal data on clinical documentation and laboratory test results (concordance 0.849) predicts progression from state III CKD to stage IV CKD more accurately when compared to a similar model without laboratory test results (concordance 0.733, P<.001), a model that only considers the most recent laboratory test results (concordance 0.819,
P < .031) and a model based on estimated glomerular filtration rate (concordance 0.779, P < .001).
Conclusions A risk prediction model that takes longitudinal laboratory test results and clinical documentation into consideration can
predict CKD progression from stage III to stage IV more accurately than three models that do not take all of these variables into
consideration.

....................................................................................................................................................
Keywords: risk prediction, electronic health records, topic modeling, survival analysis

BACKGROUND AND SIGNIFICANCE
The field of clinical disease risk prediction and progression is well developed, with hundreds of models published across many diseases.
Given their history predating electronic health records (EHRs), these
models have largely been developed with data easily accessible to clinicians. Likewise, current progression risk models for chronic kidney
disease (CKD) largely rely on commonly obtained laboratory or vital
sign data.1,2 CKD affects a large portion of the population,3 is associated with significant morbidity and mortality,4 and is a high-risk clinical condition with frequent adverse events.5,6 Despite this, patients
with kidney disease frequently go unrecognized, and their care is often
suboptimal.7–15 Early identification and more accurate prognostication
of these patients using better risk prediction models may improve outcomes by facilitating timelier initiation of appropriate therapies, monitoring, and specialty referral.16
While using readily available data for risk prediction might simplify
computation, this might be at the expense of more robust prognostication. EHRs contain much information about patient histories and patient
information conveyed both in the discrete elements of the record and in
the narratives. With increasing EHR adoption, clinical documentation is a

potentially rich, underutilized source of information that can aid in clinical decision support.17 Two aspects of the EHR in particular present an
opportunity for automated risk prediction: the presence of longitudinal
data, and the rich information conveyed in the clinical narratives.
Automated information extraction from narratives using natural language
processing (NLP) is an active field of research and has shown promising
results in estimating disease risk;18 increasing appropriate cancer
screening;19,20 and identifying post-operative complications,21 influenza,22 inflammatory bowel disease,23 pneumonia,24–26 and heart
failure.27,28
The goal of the present study was to incorporate longitudinal clinical
documentation as a novel feature in disease progression risk calculation.
While NLP has been used traditionally to look for the presence of particular pieces of information in the clinical narrative, such as presence of
signs of pneumonia,24–26 recent research in NLP and data science have
proposed methods that discover patterns from large amounts of data
that do not require a specific target. For example, one of the methods
used in this study to incorporate information from the narratives into our
risk modeling discovers topics discussed in a collection of texts in an
unsupervised fashion. Using CKD as a proof of principle, we aimed to
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METHODS
Study Population
The study cohort was derived from the clinical data warehouse of a
single institution, NewYork-Presbyterian (NYP) Hospital. The cohort
consisted of patients of an outpatient primary care clinic known as the
Associates in Internal Medicine (AIM) clinic. As of January 1, 2013, a
total of 21 580 patients were seen at the AIM clinic at least three times
with an average record length of 11.71 years (67.61) and an average
of 981.29 laboratory measurements. There are 64% females and 36%
males in this population. The earliest recorded observation for this cohort was August 23, 1988.
Patients who developed CKD stage III (defined as estimated glomerular filtration rate (eGFR) consistently <60 ml/min/1.73 m2 for 3
months) during the course of their documented clinical record were included in the cohort. The following patients were excluded from the
analysis: left censored patients (i.e., whose first documentation in their
record shows evidence of CKD stage III), patients who meet definitions
for CKD stages III and IV simultaneously, as well as HIV-positive patients and transplant patients. The study cohort was divided randomly
into development (90%) and validation (10%) cohorts.
The study was reviewed and approved by the institutional review
board at Columbia University Medical Center, and patient informed
consent was waived due to the large scale and retrospective nature of
the study.
Variables
Independent Variables
Table 1 shows the independent variables included in the five different
statistical models that were considered. Demographic variables were
age and gender (ethnicity/race variables were omitted because their
value in the EHR is left as the default value “Other” for most of the patients). All other variables, as they are time-dependent, were binned by
month and the mean value was used if multiple values were observed
within a month. To handle missing values, the most recent value was
carried forward for each bin prior to stage III onset, and for variables
that had no value for a given patient prior to stage III onset, mean values
from the development dataset were used instead.
Clinical documents included in the study consisted of discharge
summaries, and outpatient primary care and outpatient specialty
notes. The free text notes were preprocessed using the probabilistic
topic modeling technique called latent Dirichlet allocation (LDA)30,31.
LDA is a probabilistic mixed membership model often applied to text
analysis. LDA models a corpus as a set of documents, each of which

is represented by a probability distribution over a set of K topics. In
this analysis, K ¼ 50. Each topic, in turn, is represented by a probability distribution over all the terms in the vocabulary. In the generative
model for LDA, each document is generated by drawing K topics according to the weighting associated with the document and drawing N
terms, according to the weighting over terms associated with each
topic. Given this model of documents and corpora, inference amounts
to identifying the weightings over terms associated with each of the K
topics, and the weightings over topics associated with each document
given the observed documents. A Gibbs sampling approach was employed to identify the appropriate parameters. More detailed discussion of this model and methods for inference can be found in the
literature.30,31
Example topics can be seen in Tables 2 and 3, where they are represented by their most highly associated words. As LDA is an unsupervised method, these topics were automatically discovered by the
model and did not require any manual guidance. A given patient’s
notes within each time bin were thus represented as a distribution
over 50 discovered topics.
Statistical Analysis
Survival analysis
The following five multivariate Cox proportional hazards models were fit
on the development dataset: eGFR and Recent Laboratory Tests (RLT)
models and three time series models (Table 1). All models included demographic variables and all other values, as shown in Table 1, at the
time of stage III onset. All variables were standardized to have zero mean
and unit variance.
eGFR Model
This model included eGFR value, age, and gender data at stage III onset as independent variables.
RLT Model
This model considered as independent variables the values for the 19
variables included in the study prior to stage III onset.
Time series-based models
In the eGFR and RLT model, a patient’s data immediately prior to CKD
stage III onset is considered, but all other previous values are ignored.
Also, laboratory test results can be very variable depending on the
time of day, recency of meals, or other factors. Furthermore, clinical
documentation can vary significantly from note to note depending on
the author, specialty, and setting. To address this variability and simultaneously make risk predictions that incorporate longitudinal patient
data, we combine time series analysis and survival analysis to construct these risk prediction models.
The time series model used in these experiments is a variant of
the well-known Kalman filter (otherwise known as linear dynamical
systems), a time series model for noisy temporal observations which
is designed to infer a set of smooth latent (unobserved) states from
which the noisy observations are based.32,33 In our case, the noisy
observations include the laboratory test results and the clinical documentation. The model is employed such that the latent state inferred at the time of CKD three onset provides a representation
of a patient at that time, rather than the observed independent
variables.
The specification of the model is as follows: Let x i0 represents the
initial latent state for patient i , let x it be the latent state for patient i at
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develop a risk model that can provide satisfactory prediction of progression from CKD stage III to stage IV using heterogeneous sources of data.
This outcome, with a higher incidence and typically far in advance of
end-stage renal disease (ESRD), may be more meaningful for general
practitioners, providing guidance for therapy and appropriate specialty
referral.
In this study, we investigate the following research questions: (i)
How can longitudinal data from the patient record be incorporated into
risk modeling? (ii) How can EHR data be incorporated into a risk modeling paradigm, focusing on two critical data elements of the EHR, laboratory data and clinical narrative?
The family of models we investigate to represent patient documentation is unsupervised. We cast the problem of risk modeling as a survival
analysis task; thus demonstrating that these methods are capable of
producing two valuable outcomes: an interpretable set of variables associated with risk of CKD progression at the population level, and an actionable model to estimate risk of progression for individual patients.
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Table 1: Baseline statistics and independent variables for the five studied models

Independent Variables
Age

66.95 6 11.43

Gender (M/F)
eGFR

Development cohort
(n¼2617)
912 (35%)/1697 (65%)

*

50.34 6 8.47

Validation cohort
(n¼291)
67.17 6 11.69
107 (36%)/192 (64%)
50.48 6 7.60

Laboratory Test-based factors
and biases (24 variables)

eGFR
model

LKF
model

TKF
model

LTKF
model

RLT
model

X

X

X

X

X

X

X

X

X

X

X
X

RESEARCH AND APPLICATIONS

Text-based factors and
biases (60 variables)

X
X

X

25OH Vitamin D

19.18 6 7.25

16.83 6 5.11

X

Bicarbonate

25.20 6 3.06

25.23 6 3.22

X

BUN

21.45 6 8.06

21.04 6 7.75

X

Calcium

9.39 6 0.42

9.37 6 0.40

X

Chloride

102.83 6 3.50

102.64 6 3.25

X

Creatinine

1.15 6 0.34

1.10 6 0.36

X

C-reactive protein

7.70 6 8.36

6.13 6 9.86

X

Hematocrit

37.90 6 4.80

37.68 6 4.67

X

Hemoglobin

12.35 6 1.84

12.06 6 1.66

X

(K) Potassium

4.29 6 0.45

4.27 6 0.41

X

Magnesium

1.85 6 0.25

1.86 6 0.25

X

(Na) Sodium

138.97 6 2.81

138.81 6 2.71

X

Phosphate

3.41 6 0.67

3.39 6 0.63

X

Protein

7.29 6 0.66

7.43 6 0.69

X

Parathyroid Hormone

140.69 6 83.64

141.98 6 82.44

X

Triglyceride

147.85 6 72.60

154.47 6 78.15

X

Urine Protein/creatinine

32.51 6 30.56

31.21 6 29.58

X

Urine protein qualitative

2.12 6 1.02

2.12 6 0.93

X

Uric Acid

6.35 6 2.02

6.14 6 1.98

X

eGFR ¼ estimated glomerular filtration rate; LKF ¼ Laboratory Test Kalman Filter; TKF ¼ Text Kalman Filter; LTKF ¼ Laboratory Test and Text
Kalman Filter; RLT ¼ recent laboratory tests.
*
eGFR was calculated using the CKD-EPI equation.29
time t , and let v it be the observation for patient i at time t . Given these
definitions, the full model specification is:



p x i0 ¼ N 0; I r2x0


p x it ¼ N x it1 ; I r2x


p v it ¼ N W T x it þ b i ; I r2obs ;

where I is the identity matrix, N ð0; r2x0 Þ represents a multivariate
Gaussian distribution with mean zero and variance r2x0 , W is a weight
matrix representing the linear relationship between the latent state
and the observations, b i represents the observation bias terms for
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patient i , and r2x0 , r2x , and r2obs are variance parameters. After learning the model parameters, the latent state, x it , at the time of CKD
stage III and the per-patient bias terms, b i , will be used as the final
output of these models. Parameter learning in these models was
achieved through an approximation technique known as mean field
variational inference.34,35
For each of the three time series models considered, a Kalman filter was fit using the development cohort data and applied to the validation data using the previously determined parameters. When
applied to the validation data, only observations prior to the onset
of stage III CKD are used to estimate the state of the Kalman filters.
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Table 2: Topics associated with increased risk of progression. (topic titles shown in parentheses were assigned manually
once the topics were generated, and are presented as a way to label the topics)
Topic 32 (diabetes)

Topic 29 (dialysis)

Lasix

Units

q15

Volume

Insulin

Dialysis

Edema

Subcutaneous

Fistula

Heart

Lantus

Volume

Failure

Glucose

Bid

Worsening

Diabetes

Lasix

Diuresis

Times

Placement

Severe

70/30

Improved

Diastolic

Diabetic

Heparin

Overload

Days

Examined

Laboratory variables were chosen for their relatedness to CKD and associated comorbidities by a board certified nephrologist (see Table 1).
Dependent Variable
The outcome of interest was defined as progression to CKD stage IV (eGFR consistently <30 ml/min/173 m2 for 3 months).

Table 3: Topics associated with decreased risk of progression. (Topic titles shown in parentheses were assigned manually
once the topics were generated, and are presented as a way to label the topics)
Topic 33
(family history)

Topic 35
(health maintenance)

Topic 41
(non-specific)

Topic 43
(gynecological)

Topic 45
(asthma)

Died

Died

History

Breast

Albuterol

Age

Flu

Pressure

Vaginal

Asthma

Years

Visit

Rate

Mammo

Inhaled

Mother

Fasting

Count

Cancer

Lung

Father

Colonoscopy

Three

hx

Obstructive

Brother

Year

Revealed

pap

Wheezing

Sister

Shot

Times

nl

Advair

Worked

Vaccine

Shortness

Age

Pulm

Children

wnl

Discharged

Will

Restrictive

Deceased

Check

Creatinine

Endometrial

Puffs

The first time series model is called the Laboratory Test Kalman Filter
(LKF) and included the 19 laboratory test variables as input, the second time series model is called the Text Kalman Filter (TKF) and included the patient notes, as represented by their topic distributions,
and the third time series model is called the Laboratory Test and Text
Kalman Filter (LTKF) and combines the output of the LKF and TKF
models (Table 1). The output of these models are used as independent
variables in the subsequent survival analysis and include, for each patient, their inferred state at CKD stage III onset and biases for each of
the input variables that represent long term changes.

power equivalent to the area under the receiver operating characteristic
curve, was used to evaluate model performance on the validation dataset.37 Pairwise comparisons between the models were tested using the
corrected resampled t-test38 and P-values were adjusted for multiple
comparisons with the Holm-Bonferroni correction.39
All time series models were developed using the Python programming language version 2.6.5 (Python Software Foundation, Delaware,
United States) and statistical analyses were performed using R version
3.0.2 (R Foundation for Statistical Computing, Vienna, Austria).
P-values < .05 were considered statistically significant.

Prediction model validation and Experimental Setup
The coefficients and the baseline hazard function for each of the Cox
proportional hazards models36 were held constant and applied to the
validation dataset. Concordance (C statistic), a measure of discriminatory

RESULTS
Cohort Description
The development set included 2617 patients and the validation
set included 291 patients. There were 307 stage IV events in the

875

RESEARCH AND APPLICATIONS

Topic 3 (heart failure)
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Figure 1: Log hazard ratios for the eGFR Model.
Progression of CKD from stage III to stage IV in this
model was associated with low eGFR (P < .001), male
gender (P ¼ .0051), and younger age (P < .001). (* indicates P < .05, ** indicates P < .01, *** indicates
P < .001).
**

0.00
***
−0.25

−0.50

features

Gender (M)

eGFR

***

Age

RESEARCH AND APPLICATIONS

coefficients

0.25

development set and 35 events in the validation set. The average age
was 67 and there were more female (65%) than male (35%) patients
in both cohorts. (Table 1).

associated with increased risk in this model (P < .001). Topics associated with lower risk are shown in Table 3 and included terms having
to do with family history (P ¼ .031), health maintenance, (P ¼ .045),
gynecological care (P ¼ .038), and asthma (P ¼ .0045). Terms associated with all 50 topics can be found in the online supplement.
In the LKF Model, long-standing lower values for sodium
(P ¼ .047) and hematocrit (P ¼ .039) and long-standing elevated values for BUN (P < .001), creatinine (P < .001), and urine protein (quantitative, P < .001; qualitative, P < .001) were associated with higher
risk of progression (see supplement; eFigure 1).
In the LTKF model, which considered both the clinical notes and
the laboratory values, lower values of bicarbonate (P ¼ .021), elevated
levels of BUN (P ¼ .0041), creatinine (P ¼ .0013), and urine protein
(quantitative, P < .001; qualitative, P < .001), and the presence of
terms associated with heart failure (P ¼ .0017) and diabetes
(P ¼ .0042) were associated with higher risk of progression
(eFigure2). As in the TKF Model, the presence of terms associated
with asthma (P ¼ .022) was associated with a lower risk of progression. In the LKF model, the learned Kalman-filter states were also predictive of progression (details can be found in the online supplement)
The learned Kalman-filter states also had statistically significant
coefficients for predicting progression in all 3 models (details can be
found in the online supplement).
Model Performances in the Validation Cohort
Table 4 compares the performances of the 5 models on the validation
set. The concordance was highest (i.e., higher predictive ability) for
the LTKF model (0.849), followed by the LKF model (0.836), RLT
model (0.819), eGFR model (0.779) and TKF model (0.733). The LTKF
model performs significantly better than the RLT (P ¼ .031), TKF
(P < .001), and eGFR (P < .001) models, the LKF model performs significantly better than the TKF (P < .001) and eGFR (P < .001) models,
the RLT model performs significantly better than the TKF (P < .001)
and eGFR (P ¼ .007) models.

DISCUSSION
eGFR model
As shown in Figure 1, low eGFR at onset of stage III CKD was associated with high risk of progression (P < .001). Younger age was associated with increased risk of progression (P < .005). Male gender (the
variable for gender was encoded as 1 for male and 0 for female gender) was also associated with increased risk of progression
(P ¼ .005).
RLT Risk model
In the RLT model, elevated levels of BUN (P < .001), creatinine
(P < .001), triglycerides (P ¼ .0061), and urine protein (quantitative,
P ¼ .019; qualitative, P < .001), as well as decreased levels of hematocrit (P ¼ .0043), hemoglobin (P ¼ .0034), calcium (P ¼ .033), and serum protein (P ¼ .0017) were associated with increased risk of CKD
progression (Figure 2). When introducing laboratory variables at the
time of onset in the survival model, age and gender are not associated
with risk of progression anymore.
Kalman Filter Risk models
In the TKF Risk model, topics associated with a higher risk of progression are shown in Table 2 and contained terms related to heart failure
(P < .001), diabetes (P < .001), and dialysis (P ¼ .028). Mention of
these topic words throughout the course of the patient records indicated high risk for progression. Younger age was also found to be
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We have developed and performed an internal validation for five models for CKD progression from stage III to stage IV. Our models leverage
different types of variables—demographic, laboratory and/or clinical
documentation data that are collected routinely during the course of
clinical care as part of the EHR—as well as the longitudinal aspect of
the records as encoded through Kalman filters.
In absence of laboratory and documentation information, the simplest model (eGFR model) identifies that low eGFR at time of CKD
stage III diagnosis is associated with higher risk of progression.
Furthermore, younger patients with impaired kidney function (stage III
CKD) progress more rapidly toward stage IV CKD. Consistent with current knowledge of CKD, male gender was found to be associated with
more rapid loss of eGFR, and the laboratory test models (RLT) identified laboratory data known to be associated with CKD progression.1,40
We found that text is a valuable predictor for CKD progression and
that the use of time series models to characterize patient state can
substantially improve predictive accuracy for progression. In particular,
the LTKF model which incorporated demographic, laboratory, and clinical documentation data had the highest concordance of the models
considered.
With a concordance of 0.733, the TKF model predicts nearly as
well as the eGFR model where the difference did not reach statistical
significance. Variables of this model with significant coefficients
included well-known risk factors and complications of CKD including
diabetes, heart failure, and dialysis. Conversely, variables associated
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Figure 2. Log hazard ratios for the Recent Laboratory Tests Model. Progression of CKD from stage III to stage IV in this
model was associated with elevated levels of BUN (P < .001), creatinine (P < .001), triglycerides (P ¼ .0061), and urine
protein (quantitative, P ¼ .019; qualitative, P < .001) as well as decreased levels of hematocrit (P ¼ .0043), hemoglobin
(P ¼ .0034), calcium (P ¼ .033), and serum protein (P ¼ .0017). (* indicates P < .05, ** indicates P < .01, *** indicates
P < .001).
***

0.50
***

RESEARCH AND APPLICATIONS

***
*

coefficients

0.25
**

0.00
*
**
**

**

Vitamin D

Uric Acid

Triglyceride

Sodium

Quant. Urine Protein

Qual. Urine Protein

Protein

Potassium

Phosphorus

Parathyroid Hormone

Magnesium

Hemoglobin

Hematocrit

Gender (M)

Creatinine

C−Reactive Protein

Chloride

Calcium

BUN

Bicarbonate

Age

−0.25

features

Table 4. Concordances and concordance comparisons for the 5 studied models: Laboratory Test and Text Kalman Filter
(LTKF), Laboratory Test Kalman Filter (LKF), Text Kalman Filter (TKF), Recent Laboratory Tests (RLT), and estimated
Glomerular Filtration Rate (eGFR)
D LTKF

D LKF

D TKF

D RLT

D eGFR

LTKF

***

*

***

0.849

LKF

***

**

0.836

TKF
RLT
eGFR

***

Concordance

0.733
**

0.819
0.779

*P < .05, **P < .01, ***P < .001.
with a decreased risk of progression include topics indicative of documentation of health care maintenance and outpatient care. Although
the difference did not meet the significance criterion, the LKF model
performs better than the RLT model indicating that incorporating previous data in the form of a Kalman filter model can improve prognostication. The LKF model also performs significantly better than the TKF
and eGFR models indicating that laboratory tests are a particularly
valuable source of prognostic information for CKD progression. Lastly,

the LTKF model had the highest concordance at 0.849 and the significant coefficients and their directionality corresponded to variables
known to be related to CKD progression.
Risk prediction in CKD has been studied extensively, with dozens
of available risk models with acceptable performance (discrimination
0.56–0.94). Most developed classifiers use readily obtainable information, including age, demographics, and laboratory data. Hence, laboratory data, comorbidities, and occasional vital signs are the sole

877

Perotte A, et al. J Am Med Inform Assoc 2015;22:872–880. doi:10.1093/jamia/ocv024, Research and Applications

RESEARCH AND APPLICATIONS

dimensions of contemporary CKD classifiers. Age, sex, and eGFR are
included in almost all models, but fewer than half use proteinuria
(qualitative assessment or quantitative proteinuria or albuminuria), serum creatinine, serum albumin, or blood pressure. A minority of models incorporate other features, including comorbidities (e.g., diabetes,
hypertension, stroke, peripheral vascular disease, or heart failure),
common laboratory tests (e.g., serum calcium, bicarbonate, phosphorus, or cholesterol), or other vital signs (e.g., body mass index or
weight). Our work here combines a novel feature —clinical documentation—with more established features used for risk prediction to
demonstrate the potential of such an approach.
While ESRD or death as hard outcomes have significant value for
prediction, complications of CKD begin early and worsen progressively
through the various CKD stages.41–44 From stage III to IV CKD,
cardiovascular risk increases,4 anemia and bone-mineral disease
worsens,42–47 and myriad other considerations—including appropriate
dosing of medications6,48 and potential for renal replacement therapy
preparation49 —need to be evaluated. It is well known that the reporting of eGFR with routine laboratory results has led to an overall increase in nephrology referrals,11,50,51 with a concern that much of
the increase may be inappropriate.52 Patients with non-progressive
CKD stage III can often be safely and appropriately managed in the
primary care setting, whereas those apt to progress to CKD stage
IV may benefit from earlier referral to nephrologists who can assist with the medical management of CKD complications and
considerations.16,53
Although the outcome in this study is largely based on laboratory
test results (eGFR) and nephrology, as a field, is very laboratory test
oriented, it was beneficial to include features drawn the clinical
documentation. Many other fields and diseases are not as focused on
laboratory test results, and are based much more on clinical documentation. We, therefore, would expect a benefit in extending a similar
analysis to other fields and diseases.
Limitations
Because our dataset consists of a non-curated, real-world set of patient characteristics, as recorded through clinical care, there is some
potential noise in the collected variables. For instance, given the lack
of high quality information about ethnicity, we cannot assess which
ethnic groups are well represented in our dataset. This fact may introduce noise in the eGFR calculations.
The models we designed and validated are based on data from a
single institution. While there is value in focusing on a single institution
at a time (the risk predictions are relevant to the characteristics of the
institution’s patient population for instance), the model validity and its
generalizability would be better demonstrated over data from several
institutions. In particular, because of the potential variations in clinical
vocabulary and overall language in the documentation across different
institutions, there would likely be a benefit to generalizing the risk
model to patient records from other institutions. Our study requires
longitudinal documentation (both inpatient and outpatient notes over
many years, for a large set of patient records). Since there are no publicly available datasets (even de-identified) with these properties, extending this study to other datasets is outside the scope of this study
and an important limitation of the work. Short of training a model for
data from different institutions, the models presented in this study are
in theory portable to different institutions. In particular, the unsupervised NLP techniques described here (topic modeling) are actually
conducive to such an approach, as they identify patterns in the language of any given corpus without any prior knowledge of the topics
or vocabulary to expect. To address the potential differences in
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language from one institution to another, the topic models would have
to be learned on documentation from the new institutions.

CONCLUSIONS
A risk prediction model that takes longitudinal laboratory test results
and longitudinal clinical documentation into consideration can statistically significantly predict CKD progression from stage III to stage IV
more accurately than three models that do not take all of these variables nor their longitudinal aspect into consideration.

COMPETING INTERESTS
None.

FUNDING
The study was funded by the National Science Foundation (IIS1344668, IIS-0745520, IIS-1247664, IIS-1009542), The Office of
Naval Research (N00014-11-1-0651), The Alfred P. Sloan Foundation,
and The Defense Advanced Research Projects Agency (FA8750-14-20009). The funders had no role in the design and conduct of the study;
collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit
the manuscript for publication.

CONTRIBUTORS
A.P., R.R., D.B., and N.E. designed the experiments. A.P. and R.R. implemented and conducted the experiments. A.P., J.S.H., and N.E. designed the cohort selection algorithm. A.P., J.S.H., and N.E. wrote the
manuscript.

ACKNOWLEDGEMENTS
The authors would like to thank Rimma Pivovarov for the helpful discussions.

SUPPLEMENTARY MATERIAL
Supplementary material is available online at http://jamia.oxfordjournals.org/.

REFERENCES
1. Echouffo-Tcheugui JB, Kengne AP. Risk models to predict chronic kidney
disease and its progression: a systematic review. PLoS Med. 2012;9:
e1001344.
2. Tangri N, Kitsios GD, Inker LA, et al. Risk prediction models for patients with
chronic kidney disease: a systematic review. Ann Intern Med. 2013;158:
596–603.
3. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease
in the United States. JAMA. 2007;298:2038–2047.
4. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of
death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351:
1296–1305.
5. Chapin E, Zhan M, Hsu VD, et al. Adverse safety events in chronic kidney
disease: the frequency of “multiple hits.” Clin J Am Soc Nephrol. 2010;5:
95–101.
6. Fink JC, Brown J, Hsu VD, et al. CKD as an underrecognized threat to patient
safety. Am J Kidney Dis. 2009;53:681–688.
7. Abdel-Kader K, Fischer GS, Johnston JR, et al. Characterizing pre-dialysis
care in the era of eGFR reporting: a cohort study. BMC Nephrol. 2011;12:12.
8. Agrawal V, Ghosh AK, Barnes MA, et al. Awareness and knowledge of clinical practice guidelines for CKD among internal medicine residents: a national online survey. Am J Kidney Dis. 2008;52:1061–1069.

Perotte A, et al. J Am Med Inform Assoc 2015;22:872–880. doi:10.1093/jamia/ocv024, Research and Applications

27. Steinhubl SR, Williams BA, Sun J, et al. Text and data mining of longitudinal
electronic health records (EHRs) in a primary care population can identify
heart failure (HF) patients months to years prior to formal diagnosis using
the framingham criteria. Circulation. 2011;124:A12035.
28. Vijayakrishnan R, Steinhubl SR, Ng K, et al. Prevalence of heart failure signs
and symptoms in a large primary care population identified through the use
of text and data mining of the electronic health record. J Card Fail. 2014;20:
459–464.
29. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604–612.
30. Blei DM, Ng AY, Jordan MI. Latent Dirichlet allocation. J Mach Learn Res.
2003;3:993–1022.
31. Cohen R, Aviram I, Elhadad M, et al. Redundancy-aware topic modeling for
patient record notes. PLoS One. 2014;9:e87555.
32. Meinhold RJ, Singpurwalla ND. Understanding the Kalman filter. Am Stat.
1983;37:123–127.
33. Kalman RE. A new approach to linear filtering and prediction problems. J
Fluids Eng. 1960;82:35–45.
34. Wainwright MJ, Jordan MI. Graphical models, exponential families, and variational inference. Found Trends Mach Learn. 2008;1:1–305.
35. Hoffman MD, Blei DM, Wang C, et al. Stochastic variational inference. J
Mach Learn Res. 2013;14:1303–1347.
36. Cox DR. Regression models and life-tables. J R Stat Soc Ser B. 1972;34:
187–220.
37. Penciana MJ, D’Agostino RB. Overall C as a measure of discrimination in
survival analysis: Model specific population value and confidence interval
estimation. Stat Med. 2004;23:2109–2123.
38. Nadeau C, Bengio Y. Inference for the generalization error. Mach Learn.
2003;52:239–281.
39. Holm S. A Simple sequentially rejective multiple test procedure. Scand J
Stat 1979;6:65–70.
40. Iseki K. Gender differences in chronic kidney disease. Kidney Int. 2008;74:
415–417.
41. Babazono T, Hanai K, Suzuki K, et al. Lower haemoglobin level and subsequent decline in kidney function in type 2 diabetic adults without clinical albuminuria. Diabetologia. 2006;49:1387–1393.
42. Levin A, Djurdjev O, Duncan J, et al. Haemoglobin at time of referral prior to
dialysis predicts survival: an association of haemoglobin with long-term outcomes. Nephrol Dial Transplant. 2006;21:370–377.
43. Wu I-W, Hsu K-H, Lee C-C, et al. Re-evaluating the predictive roles of metabolic complications and clinical outcome according to eGFR levels – a fouryears prospective cohort study in Taiwan. BMC Nephrol. 2013;14:92.
44. Pottelbergh G V, Vaes B, Jadoul M, et al. The prevalence and detection of
chronic kidney disease (CKD)-related metabolic complications as a function
of estimated glomerular filtration rate in the oldest old. Arch Gerontol
Geriatr. 2012;54:e419–425.
45. Moranne O, Froissart M, Rossert J, et al. Timing of onset of CKD-related
metabolic complications. J Am Soc Nephrol. 2009;20:164–171.
46. Levin A, Bakris GL, Molitch M, et al. Prevalence of abnormal serum vitamin
D, PTH, calcium, and phosphorus in patients with chronic kidney disease:
results of the study to evaluate early kidney disease. Kidney Int. 2007;71:
31–38.
47. Drion I, Joosten H, Dikkeschei LD, et al. eGFR and creatinine clearance in
relation to metabolic changes in an unselected patient population. Eur J
Intern Med. 2009;20:722–727.
48. Hug BL, Witkowski DJ, Sox CM, et al. Occurrence of adverse, often preventable, events in community hospitals involving nephrotoxic drugs or those
excreted by the kidney. Kidney Int. 2009;76:1192–1198.

879

RESEARCH AND APPLICATIONS

9. Boulware LE, Troll MU, Jaar BG, et al. Identification and referral of patients
with progressive CKD: a national study. Am J Kidney Dis. 2006;48:
192–204.
10. Hemmelgarn BR, Manns BJ, Straus S, et al. Knowledge translation for nephrologists: strategies for improving the identification of patients with proteinuria. J Nephrol. 2012;25:933–943.
11. Kagoma YK, Weir MA, Iansavichus AV, et al. Impact of estimated GFR reporting on patients, clinicians, and health-care systems: a systematic review.
Am J Kidney Dis. 2011;57:592–601.
12. Lenz O, Mekala DP, Patel DV, et al. Barriers to successful care for chronic
kidney disease. BMC Nephrol 2005;6:11.
13. Tsai TT, Patel UD, Chang TI, et al. Contemporary incidence, predictors, and
outcomes of acute kidney injury in patients undergoing percutaneous coronary interventions: insights from the NCDR Cath-PCI Registry. JACC
Cardiovasc Interv. 2014;7:1–9.
14. Patel TG, Pogach LM, Barth RH. CKD screening and management in the
Veterans Health Administration: the impact of system organization and an
innovative electronic record. Am J Kidney Dis. 2009;53:S78–S85.
15. Rutkowski M, Mann W, Derose S, et al. Implementing KDOQI CKD definition
and staging guidelines in Southern California Kaiser Permanente. Am J
Kidney Dis. 2009;53:S86–S99.
16. Black C, Sharma P, Scotland G, et al. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis.
Heal Technol Assess. 2010;14:1–184.
17. Demner-Fushman D, Chapman WW, McDonald CJ. What can natural language processing do for clinical decision support? J Biomed Inf. 2009;42:
760–772.
18. Callaghan FM, Jackson MT, Demner-Fushman D, et al. NLP-derived information improves the estimates of risk of disease compared to estimates
based on manually extracted data alone. In: 5th International Symposium on
Semantic Mining in Biomedicine. 2012:18–25.
19. Wagholikar K, Chaudhry R, Boardman L, et al. Clinical decision support for
colonoscopy surveillance using natural language processing. In: 2012 IEEE
Second International Conference on Healthcare Informatics, Imaging and
Systems Biology. 2012:12–21.
20. Wagholikar KB, MacLaughlin KL, Henry MR, et al. Clinical decision support
with automated text processing for cervical cancer screening. J Am Med
Inform Assoc. 2012;19:833–839.
21. Murff HJ, FitzHenry F, Matheny ME, et al. Automated identification of postoperative complications within an electronic medical record using natural
language processing. JAMA. 2011;306:848–855.
22. Elkin PL, Froehling DA, Wahner-Roedler DL, et al. Comparison of natural language processing biosurveillance methods for identifying influenza from encounter notes. Ann Intern Med. 2012;156:11–18.
23. Ananthakrishnan AN, Cai T, Savova G, et al. Improving case definition of
crohn’s disease and ulcerative colitis in electronic medical records using
natural language processing: a novel informatics approach. Inflamm Bowel
Dis. 2013;19:1411–1420.
24. Dublin S, Baldwin E, Walker RL, et al. Natural language processing to identify pneumonia from radiology reports. Pharmacoepidemiol Drug Saf. 2013;
22:834–841.
25. Liu V, Clark M, Mendoza M, et al. Automated identification of pneumonia in
chest radiograph reports in critically ill patients. BMC Med Inform Decis
Mak. 2013;13:90.
26. Hripcsak G, Friedman C, Alderson PO, et al. Unlocking clinical data from narrative reports: a study of natural language processing. Ann Intern Med.
1995;122:681–688.

Perotte A, et al. J Am Med Inform Assoc 2015;22:872–880. doi:10.1093/jamia/ocv024, Research and Applications

49. Kinchen KS, Sadler J, Fink N, et al. The timing of specialist evaluation in
chronic kidney disease and mortality. Ann Intern Med. 2002;137:479–486.
50. Jain AK, McLeod I, Huo C, et al. When laboratories report estimated glomerular filtration rates in addition to serum creatinines, nephrology consults increase. Kidney Int. 2009;76:318–323.
51. Hemmelgarn BR, Zhang J, Manns BJ, et al. Nephrology visits and health care resource use before and after reporting estimated glomerular filtration rate. JAMA.
2010;303:1151–1158.

52. Greer RC, Powe NR, Jaar BG, et al. Effect of primary care physicians’ use of
estimated glomerular filtration rate on the timing of their subspecialty referral decisions. BMC Nephrol. 2011;12:1.
53. Smart NA, Dieberg G, Ladhani M, et al. Early referral to specialist nephrology
services for preventing the progression to end-stage kidney disease.
Cochrane Database Syst Rev. 2014;6:CD007333.

AUTHOR AFFILIATIONS
....................................................................................................................................................
1

3

2

4

Biomedical Informatics Department, Columbia University, New York, NY, USA

RESEARCH AND APPLICATIONS

Computer Science Department, Princeton University, Princeton, NJ, USA

880

Division of Nephrology, Columbia University, New York, NY, USA
Statistics Department, Columbia University, New York, NY, USA

